Trial Profile
An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 01 Aug 2016 Status changed from completed to discontinued.
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Apr 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.